X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs NOVARTIS - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA NOVARTIS SUN PHARMA/
NOVARTIS
 
P/E (TTM) x 34.3 386.0 8.9% View Chart
P/BV x 2.7 34.0 7.8% View Chart
Dividend Yield % 0.5 1.3 35.2%  

Financials

 SUN PHARMA   NOVARTIS
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
NOVARTIS
Mar-18
SUN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs701758 92.4%   
Low Rs433579 74.8%   
Sales per share (Unadj.) Rs110.4228.4 48.3%  
Earnings per share (Unadj.) Rs11.031.7 34.6%  
Cash flow per share (Unadj.) Rs17.232.8 52.6%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.41.5 23.6%  
Book value per share (Unadj.) Rs158.8297.1 53.4%  
Shares outstanding (eoy) m2,399.2624.69 9,717.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.9 175.4%   
Avg P/E ratio x51.621.1 245.2%  
P/CF ratio (eoy) x32.920.4 161.2%  
Price / Book Value ratio x3.62.2 158.7%  
Dividend payout %18.231.5 57.8%   
Avg Mkt Cap Rs m1,360,02116,505 8,239.9%   
No. of employees `00017.80.7 2,663.0%   
Total wages/salary Rs m53,6711,445 3,713.5%   
Avg. sales/employee Rs Th14,890.98,441.3 176.4%   
Avg. wages/employee Rs Th3,017.12,163.6 139.4%   
Avg. net profit/employee Rs Th1,480.61,173.1 126.2%   
INCOME DATA
Net Sales Rs m264,8955,639 4,697.7%  
Other income Rs m8,3881,718 488.1%   
Total revenues Rs m273,2827,357 3,714.5%   
Gross profit Rs m56,081-63 -89,730.1%  
Depreciation Rs m14,99825 59,282.2%   
Interest Rs m5,17655 9,359.3%   
Profit before tax Rs m44,2951,575 2,812.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452792 1,067.7%   
Profit after tax Rs m26,338784 3,361.1%  
Gross profit margin %21.2-1.1 -1,910.1%  
Effective tax rate %19.150.3 38.0%   
Net profit margin %9.913.9 71.5%  
BALANCE SHEET DATA
Current assets Rs m316,3599,522 3,322.6%   
Current liabilities Rs m198,6433,296 6,026.8%   
Net working cap to sales %44.4110.4 40.3%  
Current ratio x1.62.9 55.1%  
Inventory Days Days9537 259.0%  
Debtors Days Days10828 378.9%  
Net fixed assets Rs m213,17846 463,430.7%   
Share capital Rs m2,399123 1,944.3%   
"Free" reserves Rs m378,6067,213 5,248.9%   
Net worth Rs m381,0067,336 5,193.4%   
Long term debt Rs m17,7210-   
Total assets Rs m643,02811,105 5,790.3%  
Interest coverage x9.629.5 32.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.5 81.1%   
Return on assets %4.97.6 64.9%  
Return on equity %6.910.7 64.7%  
Return on capital %10.022.2 45.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81661 67,353.8%   
Fx outflow Rs m30,1433,630 830.4%   
Net fx Rs m10,673-3,570 -299.0%   
CASH FLOW
From Operations Rs m39,0721,610 2,427.0%  
From Investments Rs m-33,708687 -4,906.6%  
From Financial Activity Rs m-15,393-2,677 575.1%  
Net Cashflow Rs m-7,359-380 1,938.6%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 2.0 256.5%  
FIIs % 23.0 1.6 1,437.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.5 38.6%  
Shareholders   133,026 41,647 319.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare SUN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 250 Points Up; Tata Motors & Power Grid Top Gainers(12:30 pm)

Stock markets in India are presently trading higher. The BSE Sensex is trading higher by 252 points and the NSE Nifty is trading higher by 59 points.

Related Views on News

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Dec 17, 2018 12:23 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - STRIDES PHARMA SCIENCE COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS